Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

AstraZeneca (AZ), GlaxoSmithKline (GSK ... The AIC will be advised by an independent Drug Discovery Team (DDT) of ex-industry scientists who will be employed by Apollo to work with the ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

All of this by combining science, technology and the talent of GSK's people to get ahead of disease together. With that, let's now open up the call for Q&A with the team. Okay. Thank you.

GSK claims Moderna used its patented mRNA vaccine platform without a license, reaping billions from vaccine sales. The Mandl team at GSK developed a pioneering mRNA platform that has set the ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...